Sharemaestro company-news research for ProKidney Corp. (PROK), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Insufficient evidence
Company news sentiment
Latest PROK news and sentiment
ProKidney Corp.
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
No current company-news score
No company-specific headline in the last 30 days currently passes the date and relevance checks. The dash means no score; it is not a neutral observation.
Observed headline tone50/100
→
Published 30-day score50/100
Latest source headline
ProKidney Corp. (PROK) Slips 2.05% to $1.68 as Shares Sit Mid-Range Between Key Levels - Growth ETF
https://www.siam.in/ · 02 Oct 2026 15:43
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
Available information
5 current stories are mapped specifically to PROK.
Why there is no score
The stories agree, but freshness-weighted evidence is only 0.000.
Confidence is 0/100, below the threshold for a firm score.
—/100
News scoreNo qualifying directional evidence
0/100
Confidencethin evidence
0%/100
Company news5 company stories
100/100
Story agreement0/100 difference
News history
Daily score and story count over 30 days
10 Sep25 Sep09 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence0
0.0 after freshness weightingSource breadth0
0 independent publishersCompany relevance0
share tied directly to this companyFreshness16
recency-weighted evidenceAgreement100
how closely stories agreePublisher mix0
less reliance on one publisherPrice and news history
Weekly price and news-score history
No sufficiently fresh, directly relevant company news is available for a price comparison.
26 completed price weeks15 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
10 Apr07 Jul02 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
02 Oct 202650USD 1.72+7.5%
25 Sep 202650USD 1.6-16.2%
18 Sep 202650USD 1.91+6.1%
11 Sep 202650USD 1.8-10.4%
04 Sep 202651USD 2.01+9.8%
28 Aug 202649USD 1.83+13.7%
21 Aug 202647USD 1.61+21.1%
14 Aug 202647USD 1.33-18.9%
Insufficient evidence
News subjects
What is shaping the score
Market update503 stories · 60%
Balance sheet501 stories · 20%
Earnings501 stories · 20%
Source mix
Where the evidence comes from
https://www.siam.in/501 stories · 20%
GlobeNewswire501 stories · 20%
timothysykes.com501 stories · 20%
Traders Union501 stories · 20%
Insider Monkey501 stories · 20%
Recurring subjects
Subjects appearing most often
Financial Results2Clinical Trials2Chronic Kidney Disease2Cell Therapy2Earnings1Biotech1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
21 Jun50 neutral06 Oct 18:50
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 06 Oct 18:50 | 50 | +0 | 0/100 (-14) | 5 (-1) | Insufficient |
| 02 Oct 23:59 | 50 | +0 | 14/100 (0) | 6 (-1) | Provisional |
| 19 Sep 23:59 | 50 | +0 | 14/100 (-1) | 7 (-7) | Provisional |
| 11 Sep 23:59 | 50 | -1 | 15/100 (-8) | 14 (-7) | Provisional |
| 04 Sep 23:59 | 51 | +3 | 23/100 (-4) | 21 (-3) | Provisional |
| 24 Aug 23:59 | 48 | +1 | 27/100 (-8) | 24 (-3) | Provisional |
| 21 Aug 23:59 | 47 | +0 | 35/100 (-1) | 27 (+2) | Provisional |
| 20 Aug 23:59 | 47 | -2 | 36/100 (+2) | 25 (+3) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 5 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
No directional evidence to attribute yet
Company news can still be read below. Influence bars appear when a current story qualifies for the directional score.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Market updateNot used in direction
ProKidney Corp. (PROK) Slips 2.05% to $1.68 as Shares Sit Mid-Range Between Key Levels - Growth ETF
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 02 Oct 2026 15:43
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 6.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
ProKidney Seven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial mechanism of action for rilparencel One clinical abstract presents a new pooled Phase 2 analysis of patients meeting key PROACT 1 in…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
ProKidney Seven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial mechanism of action for rilparencel One clinical abstract presents a new pooled Phase 2 analysis of patients meeting key PROACT 1 inclusion criteria that continues to indicate a strong safety profile and kidney function stabilization in patients with advanced CKD and type 2 diabetes mellitus WINSTON-SALEM, N.C., Oct. 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage ce
- Published
- 02 Oct 2026 13:00
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 6.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
Cell TherapyChronic Kidney DiseaseClinical TrialsFinancial Results
—Unscored
Balance sheetNot used in direction
PROK Stock Holds Tight Range As Traders Weigh Deep Losses Against Strong Cash
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 19 Sep 2026 15:07
- News subject
- Balance sheet
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 19.6d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
ProKidney Corp. Stock Price Prediction: Today, Tomorrow, Next Week (PROK)
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 11 Sep 2026 06:46
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 28.0d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
EarningsNot used in direction
ProKidney (PROK) Nears A Pivotal Kidney Therapy Verdict
On August 10, ProKidney Corp. (NASDAQ:PROK) reported second-quarter financial results that doubled as a status update on the biggest bet in its history: a cell therapy for chronic kidney disease that is now one step closer to a verdict. The clinical-stage company completed enrollment for …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
On August 10, ProKidney Corp. (NASDAQ:PROK) reported second-quarter financial results that doubled as a status update on the biggest bet in its history: a cell therapy for chronic kidney disease that is now one step closer to a verdict. The clinical-stage company completed enrollment for the analysis that will decide whether its treatment gets an accelerated approval shot, a milestone years in the making for a drug aimed at a disease with few good options. With topline results still nearly a year away, the quarter is really about whether ProKidney can stay funded and focused long enough to get
- Published
- 11 Sep 2026 05:28
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 28.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
BiotechCell TherapyChronic Kidney DiseaseClinical TrialsEarningsFinancial Results
Earlier company news
PROK news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 43 older PROK headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to PROK, but the headline and available text are not mainly about ProKidney Corp.. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of PROK sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.